| Registro completo |
| Provedor de dados: |
BJPS
|
| País: |
Brazil
|
| Título: |
Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
|
| Autores: |
Rosa,Junior André da
Blatt,Carine Raquel
Peres,Kaite Cristiane
Storb,Bernd Heinrich
Silva,Rochele
Farias,Mareni Rocha
|
| Data: |
2012-06-01
|
| Ano: |
2012
|
| Palavras-chave: |
Hepatitis C
Hepatitis C Chronic
Effectiveness
Interferon alfa-2a
Interferon alfa-2b
|
| Resumo: |
This study aimed to evaluate the rate of sustained virological response (SVR) and the clinical and treatment characteristics of patients with chronic hepatitis C (CHC). A retrospective uncontrolled cohort study was conducted among patients who received treatment for CHC between 2005 and 2008 attended at the Center for the Application and Monitoring of Injectable Medications, in Florianopolis, SC, Brazil. The inclusion criteria were: patients over 18 years of age, with a confirmed diagnosis of chronic hepatitis C according to Brazilian guidelines, treated with PEG-IFN alfa-2a or 2b associated with RBV. A total of 188 patients were included in the study: 70% men, 59% genotype 1, 27% coinfected with HIV, 31% with cirrhosis. The SVR rate, calculated by probability theory, was determined as 26% (max=57.4% and min=12.8%) and the intention to treat was 12.8%. Associations between Sustained Virological Response (SVR) and the variables sex (p=0.017), age (p=0.003), genotype (p=0.648) and cirrhosis (p=0.275), were determined in the bivariate analysis and only sex and age were significantly associated with SVR. The SVR rate was considered low, which can be partially explained by patients' unfavorable pretreatment characteristics.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000200002
|
| Editor: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
|
| Relação: |
10.1590/S1984-82502012000200002
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Pharmaceutical Sciences v.48 n.2 2012
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
|
